Probability and impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia (CML) in chronic phase.

被引：0
|
作者：
Druker, BJ
Gathmann, I
Bolton, AE
Larson, RA
机构：
[1] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR USA
[2] Novartis Pharma, Basel, Switzerland
[3] Univ Chicago, Chicago, IL 60637 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
634
引用
收藏
页码：182A / 182A
页数：1
相关论文
共 50 条
  • [1] Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase
    Ranga Raman Ganta
    Srividya Nasaka
    Sadashivudu Gundeti
    The Indian Journal of Pediatrics, 2016, 83 : 1009 - 1012
  • [2] Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase
    Ganta, Ranga Raman
    Nasaka, Srividya
    Gundeti, Sadashivudu
    INDIAN JOURNAL OF PEDIATRICS, 2016, 83 (09): : 1009 - 1012
  • [3] Increased dose of imatinib for suboptimal response in CML in chronic phase.: Results of the Spanish registry of chronic myeloid leukemia (RELMC)
    Montero, L. F. Casado
    Giraldo, P.
    Massague, I.
    De Paz, R.
    Calle, C.
    Fores, R.
    Albizua, O.
    Burgaleta, C.
    Steegmann, J. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 249 - 250
  • [4] Comparison of combination therapy of imatinib with trisenox versus imatinib monotherapy for chronic myeloid leukemia patients in chronic phase.
    Yang, Dongguang
    Zhang, Ri
    Shen, Yunfeng
    Zhang, Xuhui
    Wu, De Pei
    BLOOD, 2006, 108 (11) : 612A - 612A
  • [5] The Role of Imatinib Plasma Level in the Achievment of Complete Cytogenetic Response (CCyR) in Chronic Myeloid Leukemia (CML) Therapy
    Kutsev, Sergey
    Oxenjuk, Oxana
    Mordanov, Sergey
    Shatokhin, Yuri
    Pospelova, Tatiana
    Khoroshko, Nina
    Turkina, Anna
    BLOOD, 2011, 118 (21) : 1619 - 1619
  • [6] Molecular response of paediatric chronic myeloid leukemia (CML) with imatinib mesylate therapy
    Dhara, Atanu
    Mukhopadhyay, S.
    Das, S.
    Mukhopadhyay, A.
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 444 - 445
  • [7] EARLY MOLECULAR RESPONSE TO NILOTINIB IN PATIENTS WHO FAILED IMATINIB IS ASSOCIATED WITH A HIGHER PROBABILITY OF CYTOGENETIC RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML)
    Hughes, T.
    Kim, D.
    Martinelli, G.
    Branford, S.
    Mueller, M.
    Beppu, L.
    Goh, H.
    Soverini, S.
    Shou, Y.
    Reynolds, J.
    Woodman, R.
    Kantarjian, H.
    Saglio, G.
    Radich, J.
    Hochhaus, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 54 - 54
  • [8] Significance of myelosuppression (MS) during the course of therapy with imatinib in patients with chronic myelogenous leukemia (CML) in chronic phase.
    Sneed, TB
    Kantarjian, HM
    Talpaz, M
    O'Brien, S
    Rios, MB
    Wierda, W
    Thomas, D
    Cortes, JE
    BLOOD, 2002, 100 (11) : 787A - 787A
  • [9] Clinical significance of molecular monitoring in chronic myeloid leukemia (CML) in chronic phase (CP) with imatinib therapy
    Cortes, J
    Talpaz, M
    O'Brien, S
    Jones, D
    Luthra, R
    Garcia-Manero, G
    Giles, F
    Shan, J
    Verstovsek, S
    Rios, MB
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 81A - 81A
  • [10] Monitoring response and treatment outcome in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib
    Teitelbaum, A.
    Spencer, D.
    Bollu, V. K.
    Chastek, B.
    Coombs, J.
    Kulakodlu, M.
    Morlock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345